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Caspases play a central role in apoptosis, inf lammation, and fibrosis. They produce hemodynamically active, proin-
f lammatory microparticles that cause intrahepatic inf lammation, vasoconstriction, and extrahepatic splanchnic vaso-
dilation. Emricasan is a pan-caspase inhibitor that lowers portal hypertension (PH) and improves survival in murine 
models of cirrhosis. This exploratory study assessed whether emricasan lowers PH in patients with compensated 
cirrhosis. This multicenter, open-label study enrolled 23 subjects with compensated cirrhosis and PH (hepatic vein 
pressure gradient [HVPG] >5 mm Hg). Emricasan 25 mg twice daily was given for 28 days. HVPG measurements 
were standardized and performed before and after emricasan. A single expert read all HVPG tracings. Median age 
was 59 (range 49-80); 70% were male. Cirrhosis etiologies were nonalcoholic steatohepatitis and hepatitis C virus. 
Subjects were Child class A (87%) with a median Model for End-Stage Liver Disease score of 8 (range 6-15). 
Twelve had severe PH (HVPG ≥12 mm Hg). Overall, there was no significant change in HVPG after emricasan 
(mean [standard deviation, SD] –1.1 [4.57] mm Hg). HVPG decreased significantly (mean [SD] –3.7[4.05] mm Hg; 
P = 0.003) in those with severe PH: 4/12 had a ≥20% decrease, 8/12 had a ≥10% decrease, and 2/12 HVPG de-
creased below 12 mm Hg. There were no significant changes in blood pressure or heart rate. Aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) decreased significantly in the entire group and in those with 
severe PH. Serum cleaved cytokeratin 18 and caspase-3/7 decreased significantly. Emricasan was well tolerated. One 
subject discontinued for nonserious adverse events. Conclusion: Emricasan administered for 28 days decreased HVPG 
in patients with compensated cirrhosis and severe PH; an effect upon portal venous inf low is likely, and concomitant 
decreases in AST/ALT suggest an intrahepatic anti-inf lammatory effect. (Hepatology 2018;0:1-12).
Portal hypertension (PH) is the main driver of decompensation and death in patients with compensated cirrhosis.(1) The initial mech-
anism is increased intrahepatic resistance to blood 
flow, but PH is maintained and enhanced by extrahe-
patic hemodynamic disturbances, including splanch-
nic vasodilation and increased cardiac output, which 
lead to increased portal venous inflow.(2)
Emricasan (IDN-6556) is an oral pan-caspase 
inhibitor that decreased apoptosis, inflammation, 
fibrosis, cirrhosis, and death in animal models of 
acute hepatitis and chronic models of nonalcoholic 
steatohepatitis (NASH).(3-5) In two NASH models, 
emricasan reduced caspase activity, apoptosis, inflam-
mation, proinflammatory cytokines, and fibrogenesis. 
In a murine model of cirrhosis induced by bile duct 
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ligation, emricasan decreased portal pressure and 
improved survival.(3) More recently, emricasan was 
studied in a rat CCl4 model of cirrhosis and was shown 
to decrease portal pressure, hepatic vascular resistance, 
inflammation, and liver fibrosis.(5) These preclinical 
studies suggested that emricasan may be effective at 
treating PH, improving hepatocellular function, and 
decreasing hepatic inflammation and fibrosis.
The aim of this exploratory study was to investi-
gate the safety and efficacy of emricasan at reducing 
portal pressure, as determined by the hepatic venous 
pressure gradient (HVPG), in patients with compen-
sated cirrhosis and PH.
Materials and Methods
sUBJects
Patients had compensated cirrhosis and PH. The 
diagnosis of cirrhosis was established by clinical, 
biochemical, imaging, and/or histological criteria. 
Compensated cirrhosis was defined by absence of 
overt ascites or encephalopathy, history of variceal 
hemorrhage, and no jaundice. Patients were required 
to have HVPG >5 mm Hg and PH based on any one 
of the following: (1) splenomegaly on imaging and/or 
clinical evaluation with platelet count of <120,000, (2) 
small varices on screening endoscopy and/or collateral 
circulation on imaging, or (3) medium/large varices 
that had never bled and had been obliterated with 
endoscopic ligation.
Exclusion criteria were age <18, decompensated 
cirrhosis defined by clinically overt ascites (requiring 
diuretics), overt encephalopathy (grade II or higher and 
requiring therapy), or history of variceal hemorrhage. 
Subjects with a history of overt ascites or grade II or 
higher encephalopathy who were currently stable (no 
ascites on physical examination and encephalopathy 
grade ≤I, with or without specific medication) were eli-
gible. Other exclusions included Child-Pugh class C; 
other nonliver organ failure; total bilirubin >12 mg/dL; 
international normalized ratio (INR) >2.5; platelets 
<20 × 109/L; overt hepatic encephalopathy of grade III 
or higher; serum creatinine >2 mg/dL; use of nonse-
lective beta-blockers (NSBBs), carvedilol, or nitrates; 
known human immunodeficiency virus infection; pan-
creatitis; portal vein thrombosis; plan to receive anti–
hepatitis C virus (HCV) therapy during the study; 
hepatitis B virus on stable therapy for less than 3 
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3
months; or hepatocellular carcinoma. An attempt was 
made to primarily enroll subjects with a history of 
NASH and/or HCV-related cirrhosis and PH.
Concomitant use of fibrates, statins, angiotensin 
II receptor antagonists, or angiotensin converting 
enzyme inhibitors was allowed if there was no change 
in dose or regimen within 3 months of screening.
Male and female subjects of childbearing potential 
were required to use two reliable forms of contracep-
tion from screening to 1 month after the last dose of 
study drug.
The study was conducted following the principles 
of the Declaration of Helsinki and approved by the 
institutional review committee of each participating 
hospital. All patients gave written informed consent.
stUDy protocol
Medical/surgical history, laboratory tests, medica-
tion record, and physical examination including vital 
signs were obtained for all subjects. Eligible subjects 
had the baseline HVPG measured prior to starting 
emricasan treatment.
This was an open-label study where all subjects 
received emricasan 25 mg orally twice a day for 28 
days. Clinical, laboratory, and safety assessments were 
performed on days 1, 7, and 28. The HVPG was 
repeated at the day 28 visit. Follow-up assessment off 
emricasan was approximately 28 days after the day 
28 visit (day 56 visit). Clinical, laboratory, and safety 
assessments were repeated at that visit.
HVpg MeasUreMeNt
Portal pressure was measured indirectly by deter-
mining the HVPG as described.(6) An HVPG study 
manual was provided to all sites, and the central HVPG 
reader ( J.B.) instructed the sites on HVPG measure-
ment procedures. Each center provided at least two 
satisfactory HVPG measurements before being qual-
ified to screen subjects. The central reader reviewed 
all HVPG tracings and provided ongoing feedback 
on technical aspects of the procedure. If a tracing was 
not adequate, the investigator was contacted promptly 
and the measurement repeated. Several tracings not 
meeting the prespecified quality criteria were subse-
quently repeated in order to obtain adequate tracings. 
All 44 tracings included in the analysis were of at least 
“adequate” quality. The procedure was performed after 
fasting all night, and sites were to perform the proce-
dure at roughly the same time of day due to circadian 
variation in HVPG measurements.
Using the transjugular approach, a balloon-tipped 
catheter was advanced into a hepatic vein under flu-
oroscopic guidance. The free hepatic venous pressure 
(FHVP) was measured with the balloon deflated and 
floating freely in the hepatic vein close to its junc-
tion with the inferior vena cava. The wedged hepatic 
venous pressure (WHVP) was measured with the bal-
loon inflated until the branch of the hepatic vein was 
completely occluded. HVPG was obtained by sub-
tracting the FHVP from the WHVP. All measure-
ments were performed in triplicate, and permanent 
tracings were obtained.
stUDy eNDpoiNts
The objectives of this study were to assess whether 
emricasan would decrease markers of caspase activa-
tion and improve portal hypertension in patients with 
compensated cirrhosis and PH. The primary end-
points of the study were change in cleaved cytokeratin 
18 (cCK18/M30), a marker of apoptosis and therefore 
of caspase activity, and change in HVPG from base-
line to day 28.
Other biomarker measures of pharmacodynamic 
activity included caspase-3/7 activity, serum amino-
transferases (alanine aminotransferase [ALT] and 
aspartate aminotransferase [AST]) and liver func-
tion (total bilirubin, INR, and albumin). Changes in 
Model for End-Stage Liver Disease (MELD) and 
Child-Pugh scores were also analyzed.
saFety assessMeNts
Safety assessments included collection of adverse 
events (AE), clinical examination, vital signs, labora-
tory tests, and electrocardiograms (ECGs). Both the 
severity of AEs and their relation to study medication 
treatment were collected.
statistical aNalyses
Because this was an exploratory study, the sam-
ple size for HVPG change from baseline was not 
statistically based. In a previously completed study 
(A8491003) that was conducted in subjects without cir-
rhosis but with chronic hepatitis C infection who had 
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failed previous HCV therapy and had elevated amino-
transferases, the observed mean change from baseline 
in log-transformed cCK18/M30 at week 10 for the 
25 mg twice daily treatment group was –0.423 with a 
standard deviation (SD) of 0.468.(7) If a similar effect 
size was observed in this study population, a sample 
size of n = 18 would provide in excess of 90% power to 
detect a change from baseline in cCK18/M30.
Baseline characteristics of patients were summa-
rized as median  SD for continuous variables and as 
percentages for nominal variables.
Analyses of the mean change from baseline in 
HVPG and log-transformed cCK18/M30 at day 28 
were conducted using a paired t test. For the HVPG 
subgroup analyses (<12 and ≥12 mm Hg), an analysis 
of variance (for HVPG) or analysis of covariance (for 
cCK18/M30) including baseline HVPG category and 
baseline value (only analysis of covariance) as factors 
were used. No adjustments for multiplicity were used 
in any of the analyses.
Additional post hoc sensitivity analyses were per-
formed for the subgroups with and without clinically 
significant PH (<10 and ≥10 mm Hg). Responder 
analyses looking at 10% improvement from baseline 
(prespecified analysis) and 20% improvement from 
baseline (post hoc analysis) were also performed using 
descriptive statistics.
The mean change from baseline in caspase-3/7 
at day 28 was summarized with descriptive statistics 
for the absolute and relative changes. The relative 
change was calculated by back-transforming the log- 
transformed changes from baseline.
Changes in aminotransferases, total bilirubin, and 
INR were tested using paired t test.
All concomitant medications that might affect por-
tal pressure, including diuretics, nitrates, antihyperten-
sives, and statins, were reviewed prior to database lock. 
No patient had new medications added or changes in 
dosages of medications that may have confounded 
interpretation of the HVPG results.
Results
sUBJect DispositioN
Subject disposition is shown in Fig. 1. Between 
October 2014 and April 2015, 30 patients were 
Fig. 1. Subject f lowchart and disposition. A total of 30 subjects were screened; 23 met the inclusion/exclusion criteria and were treated 
with emricasan. Of the 23 subjects, 22 had day 28 HVPG measurements. Data from all subjects were included in the primary efficacy 
analyses.
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screened for the study at nine sites in the United 
States and had a baseline HVPG performed. Seven 
subjects were not eligible (5 did not meet all inclu-
sion criteria, and 4 met exclusion criteria). Baseline 
characteristics of the 23 treated patients are shown 
in Table 1. Median age was 59 years, and 70% were 
male. The most common etiologies of cirrhosis 
were NASH (56.5%) and HCV (39.1%), with only 
one patient having alcoholic cirrhosis. The baseline 
median HVPG was 13.5 mm Hg (range 5.5-32.0); 
10/23 (43%) patients had HVPG <12 mm Hg with a 
median value of 7.8 mm Hg (range 5.5-11 mm Hg), 
and 13/23 (57%) patients had severe PH (baseline 
HVPG ≥12 mm Hg) with a median value of 21.5 
mm Hg (range 13-32 mm Hg). One patient (base-
line HVPG 13 mm Hg) did not complete treatment 
and withdrew on study day 1 because of AEs, none 
of which were serious or assessed as being related to 
study medication. The evaluable patient population 
consisted of 22 patients (12 with severe PH) who 
completed 28 days of treatment with emricasan and 
had day 28 HVPG measurements.
cHaNges iN HVpg
In the evaluable population (n = 22 with baseline 
and day 28 HVPG values), there was a nonsignifi-
cant trend for the HVPG to decrease after 28 days of 
emricasan (mean [SD] change from baseline of –1.1 
[4.6] mm Hg). Individual patient responses in the 
overall population are shown in Fig. 2. When patients 
were categorized by HVPG of <12 or ≥12 mm Hg, 
those with severe PH (HVPG ≥12 mm Hg, n = 12) 
demonstrated a clinically significant reduction in 
taBle 1. Baseline Demographics and Disease characteristics in the overall patient population, Baseline HVpg <12 mm 





HVPG <12 mm Hg
(n = 10)
HVPG ≥ 12 mm Hg
(n = 13)
Age 59 (48-80) 57.5 (49-71) 60 (49-80)
Gender (% male) 16 (70%) 9 (90%) 7 (54%)
Race (% Caucasian) 21 (91%) 9 (90%) 12 (92%)
Etiology of cirrhosis
NASH 13 (56.5%) 7 (70%) 6 (46.2%)
HCV only







Alcohol alone 1 (4.3%) 0 1 (7.7%)
Child-Pugh class A 20 (87%) 10 (100%) 10 (77%)
Child-Pugh class B 3 (13%) 0 3 (23%)
Esophageal varices
None 7 (30.4%) 3 (30.0%) 4 (30.8%)
Small 12 (52.2%) 7 (70.0%) 5 (38.5%)
Medium or large 4 (17.4%) 0 4 (30.8%)
BMI (kg/m2) 32.4 (17.9-44.9) 32.1 (25.4-42.4) 33.0 (17.9-44.9)
Systolic BP 126.0 (108-171) 127.0 (108-145) 126.0 (109-171)
Heart rate 76.0 (50-99) 78.5 (60-92) 76.0 (50-99)
HVPG (mm Hg)* 13.5 (5.5-32.0) 7.8 (5.5-11.0) 21.5 (13.0-32.0)
cCK18 (U/L) 191.0 (78-994) 189.0 (126, 442) 221.0 (78-994)
Caspase 3/7 (RLU) 1,997 (750-37,428) 1,598 (750-4,970) 2,305 (1,457-37,428)
MELD score 8 (6-15) 7 (6-10) 8 (6-15)
Total bilirubin (mg/dL) 0.7 (0.31-3.08) 0.6 (0.31-1.08) 0.8 (0.31-3.08)
INR 1.1 (0.9-1.6) 1.0 (1.0-1.2) 1.1 (0.9-1.6)
Albumin (g/dL) 4.2 (2.7-4.9) 4.4 (3.6-4.9) 3.9 (2.7-4.5)
Platelet count (K/mm3) 104.0 (43-199) 127.0 (63-199) 77.0 (43-191)
AST (U/L) 35.0 (16-83) 27.0 (18-71) 39.0 (16-83)
ALT (U/L) 25.0 (10-99) 23.5 (16-99) 32.0 (10-61)
Abbreviations: BMI, body mass index; BP, blood pressure.
*Values that are statistically different (P < 0.05) are indicated.
garcia-tsao et al. Hepatology, Month 2018
6
HVPG (mean [SD] –3.7 [4.0] mm Hg; P = 0.0025), 
while patients with HVPG <12 mm Hg (n = 10) did 
not (mean [SD] +1.9 [3.2] mm Hg; P = not signifi-
cant). Individual patient responses in the <12 (black) 
and >12 groups (red) are shown in Fig. 2. In the severe 
PH group, HVPG was reduced to levels <12 mm Hg 
in 2 patients (from 13.5 to 8 mm Hg and 17.0 to 9.5 
mm Hg). One third (4/12) of patients had a ≥20% 
decrease from baseline, and two thirds (8/12) had a 
≥10% decrease from baseline. The effects of emricasan 
on HVPG in patients with severe PH were similar 
in patients with different etiologies for cirrhosis (data 
not shown).
A sensitivity analysis using an HVPG cutoff of 10 
mm Hg showed similar results. The baseline demo-
graphics of the subgroups with HVPG <10 mm Hg 
and ≥10 mm Hg are shown in Supporting Table S1. 
The subgroup of subjects with a baseline HVPG of 
≥10 mm Hg (n = 15) had their HVPG decrease from 
19.1 ± 6.5 to 16.5 ± 5.8 mm Hg. At day 28, 8/15 
decreased the baseline value by ≥10%, 4/15 decreased 
the baseline value by ≥20%, and 2/15 decreased the 
baseline value to <10 mm Hg.
Although subjects using NSBBs were to be excluded 
from the study, 2 subjects taking stable doses of NSBBs 
for over 3 months were identified after treatment with 
emricasan had been initiated. These subjects remained 
in the study and were included in analyses of efficacy 
and safety. Both subjects had severe PH (baseline 
HVPG measurements of 23 and 21.5 mm Hg), and 
both had responses to emricasan treatment (HVPG 
decreases of 10 and 8.5 mm Hg, respectively).
A change in body weight between baseline and 
day 28 did not appear to confound interpretation 
of the results. Only 4 subjects gained or lost more 
than 5 lb between day 1 and day 28. One subject in 
the HVPG <12 mm Hg group gained 11 lb, and the 
HVPG increased from 8 to 17 mm Hg. Excluding 
this subject, the mean [SD] change from baseline 
at day 28 in the HVPG <12 mm Hg group was 
+1.1 [2.0] mm Hg. One subject in the HVPG ≥12 
mm Hg group gained 8.9 lb, and 2 subjects lost 8 
and 10.2 lb, respectively. Excluding them from the 
analysis yielded a mean [SD] change from baseline 
at day 28 of –3.5 [4.5] mm Hg. Thus, changes in 
HVPG followed the same pattern as that observed 
in the main analysis.
Five subjects in the study had a history of alcohol 
use disorder. Alcohol was the primary cause of cirrho-
sis in 1 subject, and contributory in 4 of the 9 subjects 
whose cirrhosis was deemed secondary to HCV. Four 
of the 5 subjects had stopped alcohol use in 1987, 
1989, 2009, and 2012, respectively. To assess the possi-
bility that surreptitious alcohol use may have affected 
the study results, a sensitivity analysis excluded those 
5 subjects. The mean HVPG decrease from base-
line at day 28 was slightly greater in this subgroup 
than in the overall population (mean [SD] change of 
–1.4 [4.7] mm Hg) but not significant. Two subjects 
were in the HVPG <12 mm Hg subgroup, and when 
excluding them, the mean [SD] change from base-
line in HVPG at day 28 was +2.3 [3.1] mm Hg (P 
= not significant). The other 3 patients were in the 
HVPG ≥12 subgroup, and when excluding them, the 
mean [SD] change from baseline in HVPG at day 28 
was –4.8 [3.2] mm Hg (P = 0.0004). Thus, changes 
in HVPG followed the same pattern observed in the 
main analysis.
Eight investigators at 9 sites enrolled the 23 sub-
jects who were treated in this study. Of the sites that 
Fig. 2. HVPG was measured at baseline and after 28 days of 
treatment with emricasan. Twenty-two subjects had baseline 
and day 28 HVPG values. Ten subjects with a baseline HVPG 
of <12 mm Hg are shown in black. In them, emricasan did not 
significantly modify the HVPG (mean [SD] +1.9 [3.2] mm Hg, 
P = 0.12). Twelve subjects who had a baseline HVPG of >12 mm 
Hg and a follow-up value at day 28 are shown in red. In those 
subjects, emricasan significantly decreased the HVPG (mean 
[SD] 3.7 [4.0] mm Hg; P = 0.003).
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enrolled subjects with severe PH, no site had more 
than 2 subjects who had a decrease in HVPG. Thus, 
there was no center effect.
cHaNges iN tHe MecHaNisM-
speciFic BioMarKer 
caspase-3/7
Changes in caspase-3/7 activity were also assessed. 
All 23 subjects had baseline and day 28 values for 
analysis. Values at baseline were clearly elevated in the 
overall patient population (median 1,997 relative light 
units [RLU], n = 23) compared to healthy subjects 
of previous studies (median of 919.5 RLU in study 
IDN-6556-05 and median of 963.5 RLU in study 
IDN-6556-08) and decreased significantly at day 28 
with emricasan treatment (mean reduction of –29.2%, 
P = 0.002) (Fig. 3A). Baseline caspase-3/7 activity was 
elevated in both HVPG subgroups but higher in the 
severe PH subgroup (median of 2,305 versus 1,598 
RLU). Reductions from baseline in caspase-3/7 activ-
ity at day 28 were qualitatively similar and statistically 
significant in both the low and high HVPG subgroups 
(mean reduction of –50.2%, P = 0.003, and –26.1%, 
P = 0.028, respectively). Caspase-3/7 activity was 
reduced in both HVPG subgroups relative to base-
line at the first postbaseline visit (mean –48.1% and 
–52.1%, respectively, at day 7; significance not tested). 
Excluding the 5 subjects with a history of alcohol use 
disorder yielded similar results, with a mean reduction 
of –57.1% at day 28 (P = 0.014). Two of the 5 sub-
jects with a history of alcohol use disorder were in the 
HVPG <12 mm Hg subgroup, and when excluding 
them, the mean change from baseline in caspase-3/7 
activity at day 28 was –42.0% (P = 0.030). The other 3 
patients were in the HVPG ≥12 subgroup, and when 
excluding them, the mean change from baseline in 
caspase-3/7 activity at day 28 was –61.5% (P = 0.157). 
Thus, the directional changes in caspase-3/7 activity 
were similar to the main analysis.
cHaNges iN ccK18
Baseline values of cCK18 in the overall popula-
tion (median 191.0 U/L) were relatively low and in 
the range of values previously observed in healthy 
subjects (median of 240 U/L in study IDN-6556-
05 and median of 162 U/L in study IDN-6556-08) 
and subjects with mild hepatic impairment (median 
of 147.5 U/L in study IDN-6556-08). Nevertheless, 
emricasan treatment decreased cCK18 values 
by a mean of 20% between baseline and day 28 
(P = 0.026) (all subjects had a day 28 value). Baseline 
cCK18 levels were also similar in each HVPG sub-
group (median baseline values of 189.0 and 221.0 
U/L in the <12 and ≥12 mm Hg HVPG subgroups, 
respectively). cCK18 values decreased more at day 
28 in the patients with baseline HVPG <12 mm Hg 
(mean 37% decrease, P = 0.001) than in the patients 
with severe PH (4% decrease, P = 0.716) (Fig. 3B). 
Fig. 3. Caspase 3/7 (A) and cCK18 (B) were measured at 
baseline and on days 7, 28 (last day on treatment), and 56 (28 
days following treatment with emricasan). Subjects were analyzed 
as follows: all subjects (gray columns), baseline HVPG <12 mm 
Hg (white columns), and baseline HVPG >12 mm Hg (black 
columns). Mean values with SD are shown for each visit. Values 
that were statistically different from baseline (P < 0.05, two-sided 
Wilcoxon signed-rank test) are indicated with an asterisk.
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There was no correlation between the change in 
HVPG and change in cCK18.
Excluding the 5 subjects with a history of alcohol 
use disorder yielded similar results, with a mean reduc-
tion of –19.7% at day 28 (P = 0.056). Two of the 5 
subjects with a history of alcohol use disorder were in 
the HVPG <12 mm Hg subgroup, and when exclud-
ing them, the mean change from baseline in cCK18 at 
day 28 was –38.5% (P = 0.017). The other 3 patients 
were in the HVPG ≥12 subgroup, and when exclud-
ing them, the mean change from baseline in cCK18 
at day 28 was –7.6% (P = 0.852). Thus, changes in 
cCK18 were qualitatively similar to the main analysis.
cHaNges iN MarKers oF 
HepatocellUlar iNJUry aND 
iNFlaMMatioN (alt aND ast)
Baseline ALT values were low in the overall patient 
group (median 25.0 IU/L) and slightly lower in the 
low versus high HVPG subgroup (23.5 and 32.0 
IU/L, respectively). Figure 4A shows the median ALT 
values by visit day. ALT decreased significantly in the 
overall population (n = 23) and in the severe PH sub-
group (n = 13) at day 28 (both P < 0.05, two-sided 
Wilcoxon signed-rank test). ALT values decreased by 
day 7 in all groups and remained lower through day 
28/end of treatment. Values tended to increase back 
toward baseline values by the day 56 visit.
A similar pattern was observed for AST. Baseline 
values in the overall group were mildly abnormal 
(median 35.0 IU/L) and lower in the low versus high 
HVPG subgroup (27.0 and 39.0 IU/L, respectively) 
(Table 1). AST decreased in the overall population 
(n = 23) and in both subgroups (Fig. 4B). AST values 
decreased by day 7 and were statistically different in 
the overall and severe PH subgroup at day 28/end of 
treatment (P < 0.05). Like ALT, AST values tended to 
increase back toward baseline values by the day 56 visit.
cHaNges iN MeasUres oF 
Hepatic FUNctioN aND 
progNosis
There were no significant changes from baseline 
in MELD score (mean change from baseline in both 
subgroups 0.0), Child-Pugh score, total bilirubin, 
INR, or serum albumin following 28 days of treat-
ment with emricasan. Two subjects (one HVPG ≤12 
mm Hg, one HVPG ≥12 mm Hg) who were Child-
Pugh class A at baseline became Child-Pugh class B 
at day 28. One subject (with HVPG ≥12 mm Hg) 
had a shift from Child Pugh class B at baseline to 
Child Pugh class A at day 28. All other subjects had 
no change in Child-Pugh class.
saFety
Treatment with emricasan was generally well tol-
erated. Overall, 60 AEs were reported by 15 subjects; 
Fig. 4. ALT (A) and AST (B) were measured at baseline and 
on days 7, 28 (last day on treatment), and 56 (28 days following 
treatment with emricasan). Subjects were analyzed as follows: all 
subjects, baseline HVPG <12 mm Hg, and baseline HVPG >12 
mm Hg. Mean values with SD are shown for each visit. Values 
that were statistically different from baseline (P < 0.05, two-sided 
Wilcoxon signed-rank test) are indicated with an asterisk.
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most were nonserious, and the most common was 
fatigue (Table 2). Three AEs reported by 1 subject 
were assessed by the investigator as serious (systemic 
inflammatory response syndrome, acute respiratory 
failure, and shortness of breath, all 3 occurring approx-
imately 10 days after the last dose of study drug). 
One subject reported four AEs, which led to discon-
tinuation from the study (eye discharge, abdominal 
distension, hypersensitivity [due to environmental 
allergy], and bilateral conjunctivitis) 1 day after start-
ing emricasan.
The number of AEs reported was higher in subjects 
in the severe PH subgroup (n = 49) than in the HVPG 
<12 mm Hg subgroup (n = 11), which was mainly due 
to 1 subject who had 27 AEs, most of which occurred 
in association with a hospitalization and subsequent 
transfusion reaction that occurred approximately 10 
days after the last dose of study drug. This subject 
had three serious AEs (the only serious AEs reported 
in the study) of systemic inflammatory response syn-
drome, acute respiratory failure, and dyspnea, con-
sidered not related to study drug. The percentage of 
subjects with AEs was similar in both subgroups (69% 
in the HVPG ≥12 mm Hg versus 60% in the HVPG 
<12 mm Hg subgroup). Most AEs were mild, and 10 
subjects reported moderate AEs (6 with HVPG ≥12 
mm Hg, and 4 with HVPG <12 mm Hg). No sub-
ject died, developed decompensating events (ascites, 
variceal hemorrhage, encephalopathy, or jaundice), 
or developed a malignancy. There were no apparent 
effects of emricasan upon non-liver-related laboratory 
tests or ECG parameters.
Systemic hemodynamics were analyzed for any 
potential effect of emricasan treatment (Table 3). There 
was no detectable effect of emricasan upon systolic 
blood pressure, diastolic blood pressure, or heart rate.
Discussion
This study assessed whether the pan-caspase inhib-
itor emricasan might decrease PH by inhibiting apop-
tosis and inflammation. Apoptosis is a hallmark of 
hepatocellular damage in many chronic liver diseases, 
including nonalcoholic fatty liver disease (NAFLD), 
hepatitis C, hepatitis B, and alcoholic liver dis-
ease.(8-11) Caspases are a family of at least 11 human 
intracellular cysteine proteases that mediate apop-
tosis and  inflammation.(12) Caspase activation and 
apoptosis result in the production of proinflamma-
tory, hemodynamically active microvesicles that lead 
to important biological effects within the liver and 
systemically.(13,14) Caspases are an important link 
between hepatocyte steatosis, lipotoxic damage, apop-
tosis, inflammation, and fibrogenesis in NAFLD. 
Caspases 2, 3/7, and 9 are integral to the induction of 
cell death by lipotoxic stress and to the pathogenesis 
of NASH-related cirrhosis.(15-20)
Microvesicle release as a result of lipotoxicity or 
ethanol exposure is also dependent upon caspase.(21-23) 
taBle 2. aes in the overall patient population, Baseline HVpg <12 mm Hg, and Baseline HVpg ≥12 mm Hg
All Subjects
(N = 23)
HVPG <12 mm Hg
(n = 10)
HVPG ≥12 mm Hg
(n = 13)
Subjects with AEs 15 (65%) 6 (60%) 9 (69%)
Subjects with serious AEs* 1 (4%) 0 1 (8%)
Subjects with severe AEs* 1 (4%) 0 1 (8%)
Subjects with AEs leading to discontinuation 1 (4%) 0 1 (8%)
Number of AEs 60 11 49
Number of AEs assessed as related 15 7 8
AEs occurring in >5% of subjects
Fatigue 5 (22%) 2 (20%) 3 (23%)
Headache 3 (13%) 3 (30%) 0
Peripheral edema 3 (13%) 1 (10%) 2 (15%)
Dehydration 2 (9%) 0 2 (15%)
Diarrhea 2 (9%) 0 2 (15%)
Constipation 2 (9%) 1 (10%) 1 (8%)
Nausea 2 (9%) 0 2 (15%)
*Subject with systemic inf lammatory response syndrome, felt to be unrelated to emricasan.
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Cannito et al. showed that steatosis and lipotoxicity 
led to microvesicle release, and that following uptake 
by hepatocytes or macrophages, the microvesicles 
caused inflammasome activation and inflammation.(24) 
These intrahepatic effects alone would provide a 
strong rationale for the use of a pan-caspase inhibitor 
in NASH.
Increased apoptosis and inflammation are also hall-
marks of active hepatitis C infection, and the result-
ing release of hepatic microvesicles/apoptotic bodies 
triggers inflammation and fibrosis upon phagocytosis 
by Kupffer cells and hepatic stellate cells.(25,26) HCV 
infection results in death receptor–mediated mito-
chondrial damage, leading to downstream caspase 
activation and apoptosis.(27) Pan-caspase inhibition 
with emricasan acutely decreased ALT levels in sub-
jects with active HCV infection.(7,28) There is there-
fore a pathophysiologic basis for believing that caspase 
inhibition may be beneficial in HCV infection as well 
as NASH.(29)
Microvesicles may also worsen PH in cirrhosis by 
acting on the increased portal blood flow, a mechanism 
that contributes to worsening PH in advanced stages, 
when the systemic circulation becomes hyperdy-
namic.(2) Microvesicles from patients with decompen-
sated cirrhosis impair the vasoconstrictor response to 
phenylephrine and decrease mean arterial pressure,(13) 
increasing portal blood inflow and worsening PH.
Microvesicles may also contribute to increased 
intrahepatic vascular resistance by increasing the 
hepatic vascular tone through changes in sinusoidal 
endothelial cell gene expression, sinusoidal remod-
eling, and reduced production of the endothelial 
vasodilator nitric oxide.(30) Caspases have been shown 
to cleave endothelial nitric oxide synthase,(31) which 
may partly contribute to the reduced nitric oxide 
availability in the liver microcirculation in cirrhosis.(32)
Emricasan treatment in the current study demon-
strated an intrahepatic effect as shown by decreases 
in ALT and AST. Elevations in ALT and AST are 
indicative of hepatocellular damage and/or inflam-
mation. This is consistent with previous studies with 
emricasan in patients with active hepatitis C and ele-
vated aminotransferase levels.(7,28) Baseline levels of 
ALT and AST were low in this study, and decreases 
in ALT and AST were more apparent in the severe 
PH subgroup, likely due to the higher baseline values 
in that subgroup, making it easier to show a treatment 
effect.
Although emricasan did not decrease HVPG in the 
overall group of patients with compensated cirrhosis, 
there was a clinically significant reduction in HVPG 
in patients with an HVPG ≥12 mm Hg and in those 
with clinically significant PH (CSPH). This is relevant 
because these are the patients who are at the great-
est risk of decompensation and in whom reductions 
in portal pressure will lead not only to a reduction in 
the development of variceal hemorrhage but also to a 
reduction in ascites, which is the most common cause 
of decompensation of cirrhosis.(33) Sensitivity analyses 
assessing the potential effects of weight loss and alcohol 
use on HVPG did not suggest a confounding effect. 
The sample size of this study was not chosen to detect 
a difference in HVPG. However, if the true treatment 
effect of emricasan is to lower HVPG 3.7 mm Hg fol-
lowing 28 days of treatment, and the variability is also 
taBle 3. change From Baseline in Hemodynamic parameters
Median
HVPG <12 mm Hg
(n = 10)




Systolic BP (mm Hg)
Baseline 127.0 126.0 126.0
Change to day 28 –2.0 0 –1.0
Diastolic BP (mm Hg)
Baseline 72.5 75.0 75.0
Change to day 28 –2.0 –2.0 –2.0
Heart rate (beats/minute)
Baseline 78.5 76.0 76.0
Change to day 28 –4.0 0 –1.0
Abbreviations: BP, blood pressure.
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as observed in this study (SD, 4.0), 12 subjects would 
have provided 81% power to detect that treatment dif-
ference using a paired t test. Additional larger studies 
in more homogeneous patient populations will be nec-
essary to better estimate the true treatment effect of 
emricasan upon HVPG.
Importantly, emricasan was generally safe and well 
tolerated, with the most common AE being fatigue 
(in 22% of the patients) and with only one patient 
developing a severe AE that was thought to be unre-
lated to the drug.
The results should be taken in the context of an 
exploratory study, with a short duration of treatment, 
a small sample size, lack of a control group or adjust-
ment for multiple testing, and without additional 
hemodynamic investigations that could provide a 
more precise mechanistic explanation of how caspase 
inhibition induced the decrease in HVPG in the sub-
group of patients with severe PH.
The acute hemodynamic effects of vasoactive drugs 
(propranolol, nadolol, vasopressin, terlipressin, soma-
tostatin, etc.) on portal pressure have routinely been 
demonstrated 15-20 minutes after intravenous admin-
istration.(33,34) For drugs acting on intrahepatic resis-
tance, simvastatin significantly decreased HVPG after 
28 days of oral administration in a double-blind, phase 
II, randomized controlled trial in patients with cirrho-
sis.(35) So, it is conceivable that changes in HVPG due 
to either intrahepatic or hemodynamic mechanisms 
were captured in the current study. Whether the por-
tal pressure–reducing effect of emricasan might be 
potentiated on longer administration should be ver-
ified in longer, adequately designed studies.
Mechanisms of PH differ in patients with mild 
portal hypertension (HVPG >5 but <10 mm Hg) 
compared to those with CSPH.(2) In mild PH, the 
main mechanism leading to portal hypertension is 
increased intrahepatic resistance, while in those with 
CSPH/varices, increased portal flow plays a major 
role in maintaining and aggravating the PH state. 
Patients with mild PH have a significantly lower 
response to NSBBs (which decrease portal flow) com-
pared to those with CSPH/varices, who have a hyper-
kinetic circulation.(33) This study suggests that the 
same may happen with emricasan, which, analogously 
to NSBBs, decreases portal pressure mostly in patients 
with severe PH.
It is unlikely that emricasan reduced intrahepatic 
resistance through an antifibrotic effect in 28 days, 
although the decreases in aminotransferases observed 
on emricasan are consistent with decreased inflamma-
tion and hepatocellular injury. Short-term decreases in 
HVPG were observed in patclarify its mechanism of 
action, and disclose whetherients with HCV cirrhosis 
shortly after achieving viral elimination, before fibro-
sis would have regressed.(36) Longer-term emricasan 
administration could further decrease portal pressure 
due to an antifibrotic effect and architectural remod-
eling, as observed in rats with cirrhosis(30) and after 
treatment of HCV-related cirrhosis where there was 
a small decrease in HVPG at the time of sustained 
virologic response but a marked decline during lon-
ger-term follow-up.(37)
In summary, this exploratory study reveals that oral 
treatment with the caspase inhibitor emricasan for 28 
days lowered portal pressure in patients with severe 
PH and was generally safe and well tolerated. The 
relatively short period of drug administration suggests 
that the decrease in portal pressure was likely due to 
a hemodynamic effect inducing a decrease in portal 
blood flow and/or in intrahepatic vascular resistance, 
although an intrahepatic effect upon hepatocellular 
damage and inflammation may also have contrib-
uted. Future randomized, placebo-controlled studies 
will elucidate the potential for additional long-term 
effects of the drug, clarify its mechanism of action, 
and disclose whether continued emricasan adminis-
tration may represent an effective treatment for cir-
rhotic PH.
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